AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUN 101 min read$INSM

Lewis William sold $613K of INSM

Lewis William (Chair and CEO) sold 6,515 shares of INSMED Inc (INSM) at $94.03 ($0.61M total) on 2026-06-08 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Lewis William
Published Jun 10, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 10, 2026, 8:15 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$INSM
Neutral
medium confidence
Mentioned
$INSM
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$INSMNeutralLow
01

Why it matters

The newest fact is the CEO/Chair’s open-market sale amount and execution date (June 8) under a pre-arranged 10b5-1 plan.

02

Market read

Traders may note the insider sale for sentiment/positioning, but the 10b5-1 structure limits fundamental read-through.

03

What to watch

The filing does not indicate whether other insiders/large holders are buying, nor does it provide context on total insider ownership changes beyond the post-transaction balance.

Relevance 4/10Novelty 5/10Timing: Filed June 10; sale executed June 8.

Background

The article is an SEC Form 4 insider transaction disclosure for INSMED Inc.

Company-level read

Ticker impact

$INSMNeutralMedium confidence
Context

INSMED CEO/Chair Lewis William filed an open-market sale of 6,515 shares (~$612.6K) under a pre-arranged 10b5-1 plan.

Expected impact

Low near-term impact; any effect is likely sentiment-driven and quickly absorbed.

Evidence & confidence

The disclosure is a Form 4 insider sale (not a buy) and is explicitly tied to a pre-arranged 10b5-1 plan, which typically reduces interpretive weight versus discretionary selling.

Market effects

Sector

Minimal; single-company insider transaction without accompanying operational/regulatory/clinical catalyst.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

10b5-1 sales can be purely mechanical; the market may overreact to the headline “insider selling” despite no new company-specific information.

Key entities

  • issuer
    INSMED Inc

    Company whose shares were sold by an insider (Lewis William).

  • insider
    Lewis William

    Chair and CEO who sold 6,515 shares on June 8, 2026 under a 10b5-1 plan.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

INSM insider trading history →

Related articles

OCT 22
$INSMMed

Brensocatib Launches in Japan for Non-CF Bronchiectasis

Insmed Inc. launched Brinsupri (brensocatib hydrate) in Japan for non-cystic fibrosis bronchiectasis, following approvals in the U.S. and Europe. The treatment, backed by clinical trial data, is the first of its kind in Japan. Insmed executives highlighted its potential to address unmet medical needs and improve patient outcomes.

ajmc.com3 min
OCT 19
$INSMHigh

Insmed launches bronchiectasis treatment in Japan

Insmed Incorporated (INSM) launched BRINSUPRI Tablets 25 mg in Japan for treating non-cystic fibrosis bronchiectasis in adults and pediatric patients 12+. The therapy, approved in August 2026, is the first of its kind in Japan. BRINSUPRI is also approved in the U.S. and EU for similar indications. Common side effects include rash, dry skin, and hypertension. Insmed is a biopharmaceutical company based in New Jersey.

investing.com1 min
OCT 19
$INSMMed

In Japan, patients can now get the only approved treatment for a lung disease that permanently widens airways.

Insmed Inc. announced that BRINSUPRI, the first approved treatment for non-cystic fibrosis bronchiectasis (NCFB), is now available by prescription in Japan. BRINSUPRI is a once-daily oral therapy designed to reduce airway inflammation. The company highlighted the substantial disease burden of NCFB and the need for effective treatments. Insmed also provided details on the drug's safety profile and potential side effects, including dermatologic and gingival adverse reactions.

stocktitan.net2 min
OCT 15
$INSMMedAI 8/10

Insmed launches four phase 3 trials for lung disease therapy

Insmed Inc. (INSM) launched four Phase 3 trials for its lung disease therapy, treprostinil palmitil. The PALM program includes studies for pulmonary arterial hypertension, pulmonary hypertension with interstitial lung disease, progressive pulmonary fibrosis, and idiopathic pulmonary fibrosis. Three trials have started, with the fourth expected in early 2027. The therapy is not yet approved.

investing.com2 min